CYCC

Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results

[GlobeNewswire] – BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

The Incredible Cyclacel Pharmaceuticals

moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments

[GlobeNewswire] – BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. (Cyclacel or the Company), today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

7:05 am Cyclacel Pharma presents non-clinical data providing rationale for Sapacitabine combination treatment with Bcr-Abl inhibitors in CML; over 800 patients have received sapacitabine in clinical studies in patients

moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Cyclacel Pharmaceuticals’ CEO Discusses Q4 2013 Results – Earnings Call Transcript

[at Seeking Alpha] – Spiro Rombotis Thank you, Bill and good afternoon. During 2013, we continued to progress clinical development of sapacitabine in patients with acute myeloid leukemia or AML and myelodysplastic syndromes … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Combination Potential of Cyclacel’s Sapacitabine and Seliciclib Reported at AACR

[at noodls] – Sequential Treatment Showed Antitumor Activity in Patients With Incurable BRCA-Deficient Cancers BERKELEY HEIGHTS, N.J., April 9, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs

[at noodls] – Novel Drug Combination Active in Patients With Incurable BRCA-Deficient Cancers WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation

[at noodls] – BERKELEY HEIGHTS, N.J., April 4, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) announced that it has entered into … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting

[at noodls] – BERKELEY HEIGHTS, N.J., April 3, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]